|
|
J Clin Invest. 1971 May; 50(5): 1080–1090. | PMCID: PMC292030 |
Immunological responses to l-asparaginase Robert G. Peterson, Robert E. Handschumacher, and Malcolm S. Mitchell Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510 Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510 Abstract In a series of 40 patients treated with L-asparaginase for various neoplastic diseases, 6 patients had generalized anaphylactic reactions to L-asparaginase. Each of these reactors had antibodies detectable by passive hemagglutination, but precipitins were detectable in only one of this group of six patients. That patient had received two courses of the enzyme. 1 wk after the anaphylactic reaction, complement-fixing antibodies were present in all the patients that were studied. Specific reagin antibodies (IgE) were demonstrated in one patient by the release of histamine from his leukocytes after incubation in vitro with L-asparaginase. Binding of L-asparaginase to serum antibodies after incubation in vitro was detected by selective precipitation of the complexes with 30% ammonium sulfate or by ultracentrifugation. Total inactivation of the enzyme did not occur even at optimal proportions or at antibody excess. Passive hemagglutinating antibodies to L-asparaginase were present in all patients who had an allergic reaction at least 1 day before the reaction occurred, when that sample was available, and were absent in all patients who did not manifest clinical allergy. Titration of antibodies by passive hemagglutination may thus provide a means of predicting impending anaphylaxis in this system, particularly when coupled with a sudden decrease in circulating levels of L-asparaginase activity. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. Images in this article Click on the image to see a larger version. These references are in PubMed. This may not be the complete list of references from this article. - Dolowy WC, Henson D, Cornet J, Sellin H. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer. 1966 Dec;19(12):1813–1819. [PubMed]
- Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW. L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA. 1967 Nov 27;202(9):882–888. [PubMed]
- Oettgen HF, Old LJ, Boyse EA, Campbell HA, Philips FS, Clarkson BD, Tallal L, Leeper RD, Schwartz MK, Kim JH. Inhibition of leukemias in man by L-asparaginase. Cancer Res. 1967 Dec;27(12):2619–2631. [PubMed]
- Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB, Serpick AA, Selawry OS. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969 Nov 6;281(19):1028–1034. [PubMed]
- Whitecar JP, Jr, Bodey GP, Harris JE, Freireich EJ. L-asparaginase. N Engl J Med. 1970 Mar 26;282(13):732–734. [PubMed]
- Mathé G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, De Vassal F, Jasmin C, Rosenfeld C. Essai de traitement de la leucémie aigue lymphoblastique par la L-asparaginase. Presse Med. 1969 Mar 15;77(13):461–463. [PubMed]
- Hill JM, Loeb E, MacLellan A, Khan A, Roberts J, Shields WF, Hill NO. Response to highly purified L-asparaginase during therapy of acute leukemia. Cancer Res. 1969 Aug;29(8):1574–1580. [PubMed]
- Ohnuma T, Holland JF, Nagel G, Arneault GS. Effects of L-asparaginase in acute myelocytic leukemia. JAMA. 1969 Dec 8;210(10):1919–1921. [PubMed]
- Clarkson B, Krakoff I, Burchenal J, Karnofsky D, Golbey R, Dowling M, Oettgen H, Lipton A. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer. 1970 Feb;25(2):279–305. [PubMed]
- Tallal L, Tan C, Oettgen H, Wollner N, McCarthy M, Helson L, Burchenal J, Karnofsky D, Murphy ML. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer. 1970 Feb;25(2):306–320. [PubMed]
- Whelan HA, Wriston JC., Jr Purification and properties of asparaginase from escherichia coli B. Biochemistry. 1969 Jun;8(6):2386–2393. [PubMed]
- Roberts J, Prager MD, Bachynsky N. The antitumor activity of Escherichia coli L-asparaginase. Cancer Res. 1966 Oct;26(10):2213–2217. [PubMed]
- Schein PS, Rakieten N, Gordon BM, Davis RD, Rall DP. The toxicity of Escherichia coli L-asparaginase. Cancer Res. 1969 Feb;29(2):426–434. [PubMed]
- Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallai L, Tan CC, Clarkson BD, Golbey RB, Krakoff IH, Karnofsky DA, Murphy ML, Burchenal JH. Toxicity of E. coli L-asparaginase in man. Cancer. 1970 Feb;25(2):253–278. [PubMed]
- Cooney DA, Capizzi RL, Handschumacher RE. Evaluation of L-asparagine metabolism in animals and man. Cancer Res. 1970 Apr;30(4):929–935. [PubMed]
- Jackson RC, Handschumacher RE. Escherichia coli L-asparaginase. Catalytic activity and subunit nature. Biochemistry. 1970 Sep 1;9(18):3585–3590. [PubMed]
- STAVITSKY AB. Micromethods for the study of proteins and antibodies. I. Procedure and general applications of hemagglutination and hemagglutination-inhibition reactions with tannic acid and protein-treated red blood cells. J Immunol. 1954 May;72(5):360–367. [PubMed]
- Mitchell MS, Wade ME, DeConti RC, Bertino JR, Calabresi P. Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Ann Intern Med. 1969 Mar;70(3):535–547. [PubMed]
- LICHTENSTEIN LM, OSLER AG. STUDIES ON THE MECHANISMS OF HYPERSENSITIVITY PHENOMENA. IX. HISTAMINE RELEASE FROM HUMAN LEUKOCYTES BY RAGWEED POLLEN ANTIGEN. J Exp Med. 1964 Oct 1;120:507–530. [PMC free article] [PubMed]
- SHORE PA, BURKHALTER A, COHN VH., Jr A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther. 1959 Nov;127:182–186. [PubMed]
- Sahiar K, Schwartz RS. The immunoglobulin sequence. I. Arrest by 6-mercaptopurine and restitution by antibody, antigen or splenectomy. J Immunol. 1965 Aug;95(2):345–354. [PubMed]
- Levy DA, Osler AG. Studies on the mechanisms of hypersensitivity phenomena. XIV. Passive sensitization in vitro of human leukocytes to ragweed pollen antigen. J Immunol. 1966 Aug;97(2):203–212. [PubMed]
- PORTNOY J, SHERMAN WB. Complement fixation studies in ragweed allergy. II. Determination of antibody in human sera to ragweed antigen by means of a complement fixation inhibition test; the relationship of antibody so determined to the passive transfer for blocking antibody. J Allergy. 1954 May;25(3):229–252. [PubMed]
- Sehon AH, Gyenes L, Kisil FT. Antibodies in sera of allergic individuals. Mod Trends Immunol. 1967;2:188–234. [PubMed]
- SCHWARTZ RH, VAUGHAN JH. IMMUNOLOGIC RESPONSIVENESS OF MAN TO PENICILLIN. JAMA. 1963 Dec 28;186:1151–1157. [PubMed]
- ARBESMAN CE, KANTOR SZ, ROSE NR, WITEBSKY E. Serum sickness: serologic studies following prophylactic tetanus antitoxin. J Allergy. 1960 May–Jun;31:257–272. [PubMed]
- GORDON J, ROSE B, SEHON AH. Detection of non-precipitating antibodies in sera of individuals allergic to ragweed pollen by an in vitro method. J Exp Med. 1958 Jul 1;108(1):37–51. [PMC free article] [PubMed]
- FRICK OL, GYENES L, SEHON AH. Demonstration of antibodies in the sera of grass-sensitive persons by the bisdiazotized-benzidine hemagglutination technique. J Allergy. 1960 May–Jun;31:216–231. [PubMed]
- Khan A, Hill JM. Neutralizing precipitin in the serum of a patient treated with L-asparaginase. J Lab Clin Med. 1969 May;73(5):846–852. [PubMed]
- Miller HK, Salser JS, Balis ME. Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy. Cancer Res. 1969 Jan;29(1):183–187. [PubMed]
|
This article has been 